Previous 10 | Next 10 |
CAMBRIDGE, Mass., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it has entered into a long-term lease agreement for a new state-of-the-art advanced cell therapy m...
CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present at the 40 th Annual J.P. Morgan Healthcare Con...
The following slide deck was published by Vericel Corporation in conjunction with this event. For further details see: Vericel Corp (VCEL) Investor Presentation - Slideshow
CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present at the Canaccord Genuity Virtual MedTech, Diagnost...
Image source: The Motley Fool. Vericel (NASDAQ: VCEL) Q3 2021 Earnings Call Nov 09, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Vericel (VCEL) Q3 2021 Earnings Call Transcript
Vericel Corporation (VCEL) Q3 2021 Earnings Conference Call November 09, 2021 8:30 AM ET Company Participants Eric Burns - Head of Financial Planning and Analysis & Investors Relations Nick Colangelo - President & Chief Executive Officer Joe Mara - Chief Financial Officer Conference C...
Vericel (NASDAQ:VCEL): Q3 GAAP EPS of -$0.11 misses by $0.08. Revenue of $34.5M (+6.8% Y/Y) misses by $3.57M. Shares +0.53% PM. Press Release Gross margin of 64%, compared to 70% in the third quarter of 2020 Non-GAAP adjusted EBITDA of $4.3 million, compared to $6.7 million in the third quart...
Third Quarter Total Net Revenue of $34.5 Million Year-To-Date 2021 Revenue Increased 38% to $108.6 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced thera...
Vericel (NASDAQ:VCEL) is scheduled to announce Q3 earnings results on Tuesday, November 9th, before market open. The consensus EPS Estimate is -$0.02 and the consensus Revenue Estimate is $38.07M (+17.9% Y/Y). Over the last 2 years, VCEL has beaten EPS estimates 75% of the time and has beaten...
CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its third-quarter 2021 financial results and busin...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the appointment of Karen Mahoney as Chief Human Resources Officer following the retirement of Heidi Hassen, w...
CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its second-quarter 2024 financial results on Thursday, August 1, 2024. Vericel’s m...
2024-07-08 00:00:04 ET Ryan Zimmerman from BTIG issued a price target of $56.00 for VCEL on 2024-07-05 10:09:00. The adjusted price target was set to $56.00. At the time of the announcement, VCEL was trading at $46.68. The overall price target consensus is at $48.00 with...